SCHEMBL13290698

SCHEMBL13290698

O=C(Nc1ccc2cc[nH]c2c1)c1oc2cccnc2c1NC(=O)[C@H]1CC[C@H](N2CCCC2=O)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXFP2 Q8WXD0 1/20 0.43
▸ NPY5R Q15761 4/20 0.41
▸ MAPT P10636 6/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ POLB P06746 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ MEN1 O00255 5/20 0.39
▸ KMT2A Q03164 5/20 0.39
▸ SYK P43405 2/20 0.38
▸ HSD17B10 Q99714 4/20 0.38
▸ TSHR P16473 3/20 0.38
▸ LMNA P02545 1/20 0.38
▸ DHODH Q02127 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ TP53 P04637 3/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ ATR Q13535 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2943587 0.90 MAPT (0.41) RXFP2MAPTKDM4EPOLBSMN1; SMN2
SCHEMBL2943586 0.90 MAPT (0.41) RXFP2MAPTKDM4EPOLBSMN1; SMN2
SCHEMBL2953858 0.89 RXFP2 (0.46) RXFP2MAPTKDM4EPOLBSMN1; SMN2
SCHEMBL2953865 0.89 RXFP2 (0.46) RXFP2MAPTKDM4EPOLBSMN1; SMN2
SCHEMBL2944781 0.85 MEN1 (0.45) NPY5RMAPTKDM4EPOLBSMN1; SMN2
SCHEMBL2944778 0.85 MEN1 (0.45) NPY5RMAPTKDM4EPOLBSMN1; SMN2
SCHEMBL13291326 0.79 NPY5R (0.45) NPY5RMAPTKDM4ESMN1; SMN2MEN1
SCHEMBL2948876 0.79 NPY5R (0.50) NPY5RSMN1; SMN2TSHRLMNATP53
SCHEMBL2948874 0.79 NPY5R (0.50) NPY5RSMN1; SMN2TSHRLMNATP53
SCHEMBL13290738 0.78 MAPT (0.41) MAPTKDM4EPOLBSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 RXFP2 2131/4885NPY5R 805/4885MAPT 4817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback